No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
Wanbangde Pharmaceutical's ALS Drug Gains FDA Orphan Drug Status
Wanbangde Pharmaceutical Holding Group (002082.SZ): The subsidiary's Mecobalamin for the treatment of amyotrophic lateral sclerosis has received FDA orphan drug designation.
Gelonghui reported on February 17 that Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., received a recognition letter from the USA Food and Drug Administration (FDA) on February 13, 2025, granting orphan drug designation for Mecobalamin for the treatment of Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease). Mecobalamin is a coenzyme of methionine synthase, which catalyzes the conversion of homocysteine to methionine, thereby maintaining the balance of the methylation cycle and reducing the neurotoxicity of homocysteine. Clinical evidence shows that patients with ALS have elevated levels of homocysteine in their cerebrospinal fluid.
Wanbangde Pharmaceutical Gets Nod to Trial Neonatal Encephalopathy Drug
Wan Bond: 2024 annual results forecast
Wanbangde Pharmaceutical Holding Group Co., Ltd. (SZSE:002082) Not Doing Enough For Some Investors As Its Shares Slump 28%
